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Introduction
Arrhythmia is one of the major causes of morbidity and
mortality in patients with chronic renal disease. There-
fore, amiodarone, an effective class III antiarrhythmic
agent, is often administered to chronic renal failure
(CRF) patients with atrial and/or ventricular arrhyth-
mias. Although amiodarone has definite advantage
over many other antiarrhythmic agents such as digoxin,
disopyramide and procainamide because of no need to
adjust dosage in renal failure patients,1 its common
side effect is thyrotoxicosis or hypothyroidism. The
overall incidence of amiodarone-induced thyroid dys-
function ranges from 2% to 24%, with most in the
range of 14–18%.2
On the other hand, recombinant human erythro-
poietin (rHuEPO) is often used to correct anemia in
CRF patients because of the diminished biosynthesis of
EPO by the diseased kidney. Does amiodarone-induced
hypothyroidism cause EPO resistance in CRF patients
who are given rHuEPO? Here, we report a patient
with CRF who developed EPO-resistant anemia after
amiodarone treatment for arrhythmia. As far as we
know, this is the first case of amiodarone-induced
hypothyroidism with EPO-resistant anemia reported.
Case Report
An 83-year-old male had been on oral prednisolone,
diuretic, angiotensin-converting enzyme inhibitor
(ACEI) and cyclosporin for membranous glomeru-
lonephritis since 1993. Renal function with slowly
progressive change was noted during follow-up at the
outpatient clinic. He began to be injected with rHuEPO
2,000 U subcutaneously twice a week to improve renal
anemia and keep serum hemoglobin level > 10 g/dL
in 2000.
After an episode of atrial fibrillation with rapid ven-
tricular response that was corrected by cardioversion in
June 2002, oral amiodarone 200 mg daily was given
to maintain normal sinus rhythm starting in July 2002.
Unfortunately, serum hemoglobin level progressively
dropped from above 10 g/dL to 8.5 g/dL without any
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active bleeding source, functional iron deficiency,
inflammation or hemolysis in March 2003.
In March 2004, hemoglobin level dropped further
to 7.2 g/dL, and the patient received blood transfusion
(Figure 1). Laboratory examinations for serum iron,
vitamin B12, folic acid, C-reactive protein and hepa-
toglobulin level were all within normal ranges, except
for low serum triiodothyronine level of 45.59 ng/dL
(reference range, 60–181 ng/dL), low free thyroxine
level of 2.55ng/dL (reference range, 4.5–12.5ng/dL),
and high thyroid-stimulating hormone (TSH) level of
13.441 uIU/mL (reference range, 0.4–4.0 uIU/mL).
Serum intact parathyroid hormone level was 158 pg/
mL. Serum calcium and phosphate levels were 7.5 mg/
dL and 3.3 mg/dL, respectively. The patient was not
on any medication containing aluminum. Therefore,
hypothyroidism due to amiodarone was impressed.
As hemoglobin level did not increase even after amio-
darone was discontinued, rHuEPO was increased to
2,000 U thrice weekly in June 2004.
However, due to the economic burden of rHuEPO
2,000 U 3 times a week and persisting hypothyroidism
with no improvement in hemoglobin (thyroxine
3.74 ng/dL and TSH 6.76 ng/dL in August 2004),
the dosage of rHuEPO was decreased to 2,000 U twice
a week and oral thyroxine was given in September
2004. After the supplement of thyroxine, thyroid func-
tion became normal within 3 months (Figure 1). Thy-
roxine and TSH levels were, respectively, 5.56 ng/dL
and 0.26 ng/dL in December 2004. Hemoglobin level
increased rapidly from around 7.5 g/dL to 9.5 g/dL
after thyroxine administration (Figure 1).
In August 2002, serum creatinine (Cr) level and cre-
atinine clearance (Ccr) were 4.0 mg/dL and 19 mL/
min, respectively. Serum Cr level and Ccr were 5.1mg/
dL and 8.5 mL/min, respectively, in January 2005.
In the following 30 months, ACEI was continuously
prescribed, and thyroid function was normal under
maintenance thyroxine therapy. Hematocrit was >30%
under a dose of rHuEPO 2,000 U twice a week.
Discussion
Chronic renal disease is often accompanied by nor-
mocytic anemia and cardiovascular disease, especially in
elderly patients,3 and EPO therapy has proven to be
very effective in the treatment of anemia in patients with
CRF. In our patient, rHuEPO 2,000 U subcutaneous
injection 2 times a week was initially administrated for
renal disease-related anemia, and it could maintain
serum hemoglobin level above 10 g/dL. However, 
hemoglobin level progressively dropped to 7 g/dL
from > 10 g/dL during amiodarone treatment for
atrial fibrillation with rapid ventricular response rate.
Evidence that the drop in hemoglobin level was 
amiodarone-related included: (1) there was no episode
of iron deficiency, folate deficiency, vitamin deficiency,
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Figure 1. Clinical course and treatment of amiodarone-induced hypothyroidism with erythropoietin-resistant anemia. Thyroid-stimulating
hormone (TSH) level before and after levothyroxin supplement. EPO = erythropoietin; BT = blood transfusion with 2 units of packed red
blood cells; T4 = thyroxine. *Duration of EPO 2,000 U/TIW.
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blood loss, inflammation, hyperspleenism, hemolysis,
severe hyperparathyroidism, aluminum toxicity and
hemoglobinopathy;4 (2) amiodarone-induced hypothy-
roidism occurs more frequently than amiodarone-
induced thyrotoxicosis in iodine-sufficient areas3
(incidence of amiodarone-induced hypothyroidism is
5–7% and 13–22% in regions with low and high dietary
iodine intake, respectively);5,6 (3) it has been estimated
that a third to half of patients with hypothyroidism
have some decrease in the normal red blood cell mass;7
(4) hypothyroidism could also induce EPO resistance;8
(5) if the severity of anemia is roughly proportional to
the degree of azotemia, the hemoglobin level should
not increase rapidly after thyroxine supplement; and
(6) the dosage of rHuEPO did not increase during
medication with thyroxine.
The mechanism of amiodarone-induced hypothy-
roidism in susceptible patients is thought to result from
abnormal response of the thyroid to a chronic high
iodine load and then inability to resume normal thyroid
function from the inhibitory effect (Wolff-Chaikoff
effect) of iodine uptake and hormone synthesis.9 Be-
cause iodine is cleared mainly by the kidneys, patients
with CRF may develop thyroid dysfunction when ex-
posed to large doses of iodine.10 Though the clearance
of amiodarone seems not to be influenced in renal
failure patients,1 there were no available data to show
the frequency or severity of hypothyroidism if the pa-
tient has chronic renal disease and is using amiodarone
concomitantly. In this case, diagnosis of amiodarone-
induced EPO resistance due to hypothyroidism, the
major side effect of amiodarone, was delayed by lack of
early regular detection of thyroid function. Thyroxine
was also given late due to the wait for the recovery of
thyroid function after amiodarone was discontinued.
Therefore, we suggest early regular detection of thyroid
function in patients on amiodarone, especially in pa-
tients with CRF. Early administration of thyroxine is
better than waiting for the spontaneous recovery of
thyroid function.
In conclusion, amiodarone-induced hypothyroidism
should be put in the differential diagnosis of unexplain-
ed progressive EPO-resistant anemia in patients with
chronic renal disease. Early thyroxine administration is
better than waiting for the spontaneous recovery of thy-
roid function for hemoglobin improvement in CRF
patients with amiodarone-induced hypothyroidism.
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